New VITROS XT 3400 Chemistry System from Ortho Clinical Diagnostics Enhances Its VITROS XT Solutions, Offering Labs Faster, More Accurate Results and Trusted System Reliability to Ensure Better Patient Outcomes

RARITAN, N.J., Feb. 26, 2020 /PRNewswire/ -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory solutions, today announced the launch and availability of the VITROS XT 3400 Chemistry System, which completes the company's VITROS XT Solutions, a comprehensive suite of solutions that help labs obtain consistently fast, accurate and reliable results.

VITROS XT Solutions, which include the new VITROS XT 3400 Chemistry System and the VITROS XT 7600 Integrated System with new XT MicroSlides, help ensure the right result the first time, expediting critical health information to clinicians who can make decisions faster and ultimately improve patient outcomes.

"Because Every Test is a Life, we make patient care our passion at Ortho Clinical Diagnostics," said Chris Smith, chief executive officer, Ortho Clinical Diagnostics. "Driven by this, we work diligently to ensure the world's labs are best equipped to partner with clinicians and medical teams to provide consistently fast, accurate results that help them confidently diagnose, monitor and treat their patients."

"Like many industries, the diagnostic space is under constant pressure to do more with less, and often, that starts in the lab—the hub of the health care journey," said Piper Antimarino, Ortho's head of clinical labs product portfolio. "Our team has spent countless hours speaking with lab directors and decision makers across hospitals, health care systems, and emergency departments to truly understand their realities and challenges. We are proud to introduce industry-changing products like our VITROS XT Solutions designed to help them succeed by driving efficiencies, reducing costs and improving patient outcomes."

Results Processed Without Operator Interventions

VITROS XT Solutions ensure the right result the first time with an industry-leading 96.5 percent first-pass yield.ⁱ Further, they reduce the need for manual interventions such as those caused by reviews, reruns or redraws by 75 percent compared to competitive systems.ⁱⁱ For labs doing one million tests per year, this provides up to 300 more tests per day without delay. Ortho further reduces delays through its systems' uptime, in some markets guaranteeing 98 percent uptime to e-Connected VITROS customers.ⁱⁱⁱ